Home > Press > Case and partners receive $4M to make ‘smart nanoparticles’
Cleveland Clinic, Case and partners receive $37 million in total from State of Ohio
Case School of Medicine and partners receive $4 million to make ‘smart nanoparticles’
May 14, 2005
The School of Medicine received $4 million in funding from the State of Ohio’s Third Frontier Initiative for Targeted Nanoparticles for Imaging and Therapeutics (TNIP), which will support the development and commercialization of sub-atomic particles for the early detection of breast cancers and new therapies for hemophilia. Case Western Reserve University will work in collaboration with University Hospitals of Cleveland and local companies Cleveland NanoCrystals, Copernicus Therapeutics, Inc., Ferro Corp., and Ricera Biosciences, Inc. Principal investigator for TNIP is Pamela B. Davis, M.D., Ph.D., professor of pediatrics at Case and University Hospitals of Cleveland and senior associate dean for research at the School of Medicine.
Davis said the plan is to create smart nanoparticles that can accomplish several things:
- Light up on imaging only at sites of disease,
- Deliver photoactivated molecules to cancerous lesions so as to kill the tumors, not the healthy tissue around them,
- Deliver payloads of corrective genes to treat genetic disorders, and payloads of inhibitory nucleic acids to suppress viral infections or cancers,
- Deliver effective drugs that are otherwise too toxic or too insoluble to be used in humans.
“There is a full plan to develop not only the science but also to bring the drugs to market so that people can have access to them and benefit,” said Davis. “Diseases that are targeted are hemophilia, viral infections and cancer.”
The grant was announced by Lt. Gov. Bruce Johnson as part of a $75 million grant package handed out throughout the state. More than half the funding will come to Northeast Ohio.
In addition to the nanoparticles grant, the Cleveland Clinic Foundation, Case Western Reserve University and collaborating businesses received two grants for the creation of the Atrial Fibrillation Innovation Center. A Wright Center of Innovation (WCI) grant, worth $15 million, and a Biomedical Research and Technology Transfer Partnership Program (BRTT), worth $8 million, will enable the center to develop both surgical and non-invasive treatments to prevent and cure dangerous electrical disturbances of the heart that dramatically increase the risk of stroke and death. Other Ohio partners include the University of Cincinnati and AtriCure, Inc. in Cincinnati, which provides doctors with alternative, more effective surgical technologies.
The Cleveland Clinic and Case also will partner with Wright State University in Dayton to use a $6 million BRTT grant for the AMD Initiative for Prevention and Cure. The AMD project will develop a diagnostic test to identify individuals at risk for adult macular degeneration and to develop techniques for the early diagnosis and treatment of the disease.
Additionally, the Cleveland Clinic Foundation and Case will join collaborators across Ohio and the nation to use a $4 million BRTT grant to create the Clinical Tissue Engineering Center (CTEC), which will create new therapies for the repair and regeneration of bone, cartilage, tendon and skin. Target diseases include osteoarthritis, fracture care, osteoporosis, traumatic or degenerative tendon rupture, and acute and chronic soft tissue wounds.
Johnson said that the grants will help accelerate the commercialization of new products and strengthen Ohio’s role in the knowledge economy. “Through the Third Frontier Project, we are reclaiming Ohio’s culture of innovation,” said Johnson, who also serves as director of the Department of Development and chair of the Third Frontier Commission. “These grants build upon Ohio’s research strengths and focus on the development of new products in order to strengthen our economy and create good jobs.”
In collaboration with The Ohio State University Research Foundation and others, the Cleveland Clinic Foundation is receiving a BRTT grant of $4.25 million for a Commercialization Platform of Immunotherapeutics for Multiple Sclerosis, which will develop and commercialize new therapies involving the body’s immune system to delay and control the onset of multiple sclerosis.
Goodyear Tire & Rubber Co., Kent State University, the Sherwin-Williams Co., the Timken Co., the University of Akron, and various other state and national collaborators will work with The Ohio State University to develop the Center Ohio Center for Multifunctional Polymer Nanomaterials and Devices (CMPND). The $22.5 million WCI grant will provide for the acquisition of highly advanced equipment to develop new materials that will improve the strength and durability of components that will be part of automobiles and other manufactured products. CMPND will include a broad-based research, business and outreach program centered at OSU with regional sites at the University of Akron and the University of Dayton and more than 50 company collaborators across Ohio. The project also will have support from the Ohio Polymer Strategy Council.
The Wright Centers of Innovation support large-scale world-class research and technology development platforms designed to accelerate the pace of new product development in Ohio. Wright Centers are characterized by collaboration among Ohio’s higher education institutions, non-profit research organizations and Ohio companies in the areas of advanced materials, bioscience, power and propulsion, information technology and instruments, controls and electronics. The proposals are independently reviewed by the National Academy of Sciences and selected by the Third Frontier Commission.
One additional WCI recipient was OSU’s College of Food, Agricultural and Environmental Sciences and its business collaborators, who will receive a $11.6 million grant for the creation of the Ohio BioProducts Center. The center will develop chemical conversion technologies to produce products such as lubricants and adhesive from raw materials grown in Ohio, including corn and soybeans, giving Ohio farmers a new market for their goods.
“The Ohio BioProducts Innovation Center is a perfect example of how the Third Frontier can benefit Ohio’s First Frontier, agriculture,” said Johnson. “High-tech advances in polymers have the potential for opening up new markets for Ohio-grown products.”
The BRTT Program supports biomedical and biotechnology research intended to lead to job creation and improvements in the health of Ohioans. Awarded projects are collaborations among Ohio higher education institutions, non-profit research organizations and Ohio companies in the areas of human genetics and genomics, structural biology, biomedical engineering, computational biology, plant biology and environmental biology. Like the Wright Center awards, they are reviewed by the National Academy of Sciences and selected by the Third Frontier Commission.
A 10-year, $1.1 billion initiative, the Ohio Third Frontier Project is the state’s largest-ever commitment to expand Ohio’s high-tech research capabilities and promote start-up companies to create high-paying jobs for generations to come.
More information about Nanoparticle for Human Therapeutics and Diagnostic Imaging from the grant application:
This application will develop nanoparticles for human therapeutics and diagnostic imaging and bring them to market to improve the health of Ohioans. Nanoparticles consist of a payload, a biocompatibility component, and sometimes targeting ligands. Payloads fall into three categories: 1) nucleic acids, such as DNA for gene therapy of genetic diseases, or siRNAs to silence genes that contribute to pathology in man, such as cancer or viral infections; 2) small molecules that may be too toxic, insoluble, or fragile to be administered alone, such as drugs intended to kill tumor cells or control blood clotting within vessels; and 3) molecules for imaging, such as nanocrystals that emit light of particular wavelength, or molecules that signal in magnetic resonance spectrometers. Targeting moieties deliver nanoparticles directly to their intended site of action. The program subsumes scientific projects already funded elsewhere, novel scientific projects, and cores to facilitate the rapid development of nanoparticles from idea to product. Cores range from Molecular and Analytical Cores to Animal, Imaging, and GLP Cores: most are already equipped and operational. In parallel to the scientific program, and strongly interactive with it, is a commercialization program for protection of intellectual property, obtaining initial support to validate the intended use of the nanoparticles, and catalyzing funding to launch or expand commercialization of nanoparticles and bring them to market. This program capitalizes on strong well funded science of nanoparticles already present at Case, as well as that at local companies, and on the commercial expertise in the Case tech transfer office, local companies, and venture funds. We include professors experienced in commercialization, brilliant assistant professors with marvelous new ideas, companies freshly minted, and others that are established in manufacture. Some nanoparticles have passed Phase I clinical trial; others are in development. This range of talents and products bode well for rapid, synergistic scientific development and advance of products to market.
Pamela B. Davis, Case Western Reserve University, Principal Investigator; James Ault, Ricerca Biosciences, LLC, Core Director; Mark Brandt, Maple Fund, Commercialization Council; Clemens Burda, Case Western Reserve University, Co-investigator; Mark Cooper, Copernicus Therapeutics, Inc., Project PI, Core Director; Patrick E. Crago, Case Western Reserve University, Advisory Board; Mitch Drumm, Case Western Reserve University and University Hospitals of Cleveland, Core Director; Jeffrey Duerk, Case Western Reserve University and University Hospitals of Cleveland, Core Director; Maryann Fitzmaurice, Case Western Reserve University, Project PI; Joe Jankowski, Case Western Reserve University, Co-investigator; Malcolm E. Kenney, Case Western Reserve University, Co-investigator; Carl Lentz, Ferro Corporation, Advisory Board; Roger Marchant, Case Western Reserve University, Co-Investigator; Robert Moen, Copernicus Therapeutics, Inc., Co-investigator; Nancy L. Oleinick, Case Western Reserve University, Project PI; Mark Pagel, Case Western Reserve University, Project PI ; Donna Richardson, Cleveland Nanocrystals, Co-Investigator; Andrew M. Rollins, Case Western Reserve University, Co-Investigator; David M. Stout, Ricerca Biosciences, LLC, Co-Investigator; Anna van Heeckeren, Case Western Reserve University and University Hospitals of Cleveland, Core Director; Michael Watson, Ricerca Biosciences, LLC , Co-investigator; Stuart J. Youngner, Case Western Reserve University, Advisory Board; Assem G. Ziady, Case Western Reserve University and University Hospitals of Cleveland, Project PI.
About Case Western Reserve University:
Case is among the nation's leading research institutions. Founded in 1826 and shaped by the unique merger of the Case Institute of Technology and Western Reserve University, Case is distinguished by its strengths in education, research, service, and experiential learning. Located in Cleveland, Case offers nationally recognized programs in the Arts and Sciences, Dental Medicine, Engineering, Law, Management, Medicine, Nursing, and Social Sciences.
For more information www.case.edu
Copyright © Case Western Reserve University
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Conference speakers: International think tank needed to identify techno-social turning points December 6th, 2013
Bangalore INDIA NANO 2013 Inaugurated December 5th, 2013
3-D printing and custom manufacturing: from concept to classroom: Strategic investments from NSF help engineers revolutionize the manufacturing process December 5th, 2013
The promise of nanotechnology December 4th, 2013
Harris & Harris Group Notes ABSMaterials' Series B Financing November 22nd, 2013
Harris & Harris Group Letter to Shareholders on Website November 18th, 2013
Harris & Harris Group Reports Financial Statements as of September 30, 2013 November 12th, 2013
Harris & Harris Group Notes CordenPharma's Acquisition of Ancora's Carbohydrate Synthesis Platform and Corporate Name November 7th, 2013
Nanobiotix strengthens its NanoXray pipeline with the launch of NBTX-TOPO development, the first nanotherapeutic with embedded radar: 1 product, 2 skills December 6th, 2013
The gene sequencing that everyone can afford in future December 6th, 2013
Dissolving electronics, energy: Kavli lectures at American Chemical Society meeting December 5th, 2013
Laser light at useful wavelengths from semiconductor nanowires: Nanowire lasers could work with silicon chips, optical fibers, even living cells December 5th, 2013
Leti Presentation at IEDM 2013 Will Report Phase-Change Memory Developments for Microcontroller Embedded Applications December 7th, 2013
Leti Announces Update of UTSOI Model that Allows Designers To Improve Trade-Off between Performance and Power Use December 7th, 2013
Steve Janack to Join Behan Communications and Lead Firm’s New Innovation Practice Group December 7th, 2013
Optical Quality Improvement of Electrical Circuits’ Electrode Zinc Oxide Nanowires December 7th, 2013